CRISPR Therapeutics (CRSP) Stock Forecast & Price Target $46.25 -1.01 (-2.14%) (As of 11/21/2024 ET) Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CRISPR Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024) How MarketBeat Calculates Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Consensus Rating HoldBased on 19 Analyst RatingsSell2Hold8Buy9 Based on 19 Wall Street analysts who have issued ratings for CRISPR Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 19 analysts, 2 have given a sell rating, 8 have given a hold rating, and 9 have given a buy rating for CRSP. Consensus Price Target $74.9462.03% Upside According to the 19 analysts' twelve-month price targets for CRISPR Therapeutics, the average price target is $74.94. The highest price target for CRSP is $105.00, while the lowest price target for CRSP is $30.00. The average price target represents a forecasted upside of 62.03% from the current price of $46.25. Get the Latest News and Ratings for CRSP and Related Stocks Enter your email address to receive the latest news and analysts' ratings for CRISPR Therapeutics and its competitors. Enter your email to sign up for newsletter Sign Up CRSP Analyst Ratings Over TimeTypeCurrent Forecast11/23/23 to 11/22/241 Month Ago10/24/23 to 10/23/243 Months Ago8/25/23 to 8/24/241 Year Ago11/23/22 to 11/23/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy9 Buy rating(s)9 Buy rating(s)9 Buy rating(s)9 Buy rating(s)Hold8 Hold rating(s)8 Hold rating(s)8 Hold rating(s)5 Hold rating(s)Sell2 Sell rating(s)2 Sell rating(s)2 Sell rating(s)1 Sell rating(s)Consensus Price Target$74.94$75.19$75.63$69.88Forecasted Upside62.03% Upside63.45% Upside55.32% Upside-0.86% DownsideConsensus RatingHoldHoldHoldModerate Buy What Comes Next Could Be a Once-in-a-Lifetime Opportunity (Ad)A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.Click here now to watch the full briefing and discover the steps to take today. CRSP Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History CRSP Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table CRISPR Therapeutics Stock vs. The CompetitionTypeCRISPR TherapeuticsMedical CompaniesS&P 500Consensus Rating Score 2.37 2.80 2.50Consensus RatingHoldModerate BuyModerate BuyPredicted Upside62.03% Upside26,677.67% Upside8.51% UpsideNews Sentiment RatingPositive NewsSee Recent CRSP NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails11/6/2024Royal Bank of Canada4 of 5 stars Reiterated RatingSector Perform ➝ Sector Perform$53.00 ➝ $53.00+5.98%11/6/2024Barclays3 of 5 stars Lower TargetEqual Weight ➝ Equal Weight$59.00 ➝ $55.00+9.21%11/6/2024Needham & Company LLC3 of 5 stars Reiterated RatingBuy ➝ Buy$84.00 ➝ $84.00+66.80%8/12/2024Truist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetBuy ➝ Buy$120.00 ➝ $100.00+110.84%8/8/2024Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingNeutral8/6/2024Chardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetBuy ➝ Buy$112.00 ➝ $94.00+89.29% Get the Latest News and Ratings for CRSP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/6/2024Stifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetHold ➝ Hold$60.00 ➝ $59.00+18.81%8/2/2024Rodman & RenshawSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageBuy$90.00+64.08%6/28/2024GuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingD. ChattopadhyaySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral6/17/2024Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOverweight ➝ Overweight$105.00 ➝ $105.00+71.65%5/23/2024CitigroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetBuy ➝ Buy$89.00 ➝ $84.00+50.27%5/10/2024OppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetOutperform ➝ Outperform$102.00 ➝ $95.00+85.19%5/9/2024JMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingMarket Outperform ➝ Market Outperform$86.00+61.65%5/9/2024Wells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetEqual Weight ➝ Equal Weight$70.00 ➝ $65.00+24.12%5/9/2024Robert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetNeutral ➝ Neutral$46.00 ➝ $52.00-2.42%3/6/2024MizuhoSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetBuy ➝ Buy$82.00 ➝ $99.00+22.24%2/26/2024Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetUnderweight ➝ Underweight$46.00 ➝ $48.00-43.64%2/15/2024Wolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoveragePeer Perform12/11/2023TD CowenSubscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeMarket Perform ➝ Underperform$30.00-53.52%8/8/2023Credit Suisse GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetNeutral ➝ Neutral$62.00 ➝ $63.00+30.33%5/30/2023William BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingS. CorwinSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$75.00+15.99%5/9/2023VNET GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingReiterates4/17/2023EF Hutton Acquisition Co. ISubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingBuy$75.00+38.63%3/21/2023Sanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageMarket Perform$44.00-1.03%3/17/2023Bryan, Garnier & CoSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageBuy$70.00+54.22%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 06:51 AM ET. CRSP Forecast - Frequently Asked Questions What is CRISPR Therapeutics' forecast for 2025? According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for CRISPR Therapeutics is $74.94, with a high forecast of $105.00 and a low forecast of $30.00. Should I buy or sell CRISPR Therapeutics stock right now? 19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last twelve months. There are currently 2 sell ratings, 8 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CRSP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRSP, but not buy additional shares or sell existing shares. Does CRISPR Therapeutics's stock price have much upside? According to analysts, CRISPR Therapeutics's stock has a predicted upside of 62.03% based on their 12-month stock forecasts. What analysts cover CRISPR Therapeutics? CRISPR Therapeutics has been rated by research analysts at Barclays, Needham & Company LLC, and Royal Bank of Canada in the past 90 days. Do Wall Street analysts like CRISPR Therapeutics more than its competitors? Analysts like CRISPR Therapeutics less than other "medical" companies. The consensus rating for CRISPR Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CRSP compares to other companies. Stock Forecasts and Research Tools Related Companies ALLO Stock Forecast SGMO Stock Forecast FATE Stock Forecast ADVM Stock Forecast CLLS Stock Forecast BLUE Stock Forecast DTIL Stock Forecast MRNA Stock Forecast NBIX Stock Forecast TECH Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter BREAKING: NVDA loses $175 billion in 8 minutes (Ad)It's a wild week for the legendary chipmaker. Nvidia just beat earnings expectations across every metric, with annual revenue up nearly 100%. So why did the stock abruptly plunge following the earnings release – losing $175 billion in just 8 minutes?Things are about to get even stranger. This page (NASDAQ:CRSP) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredMy favorite credit card just increased its sign-up bonusTired of getting average credit card rewards? This credit card just increased its sign-up bonus to 75,000 bonu...Card Ratings | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhy Buffett, Bezos & Congress Are Rushing Into This SectorWhy are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRSP Stock Alerts